Zusammenfassung
Diabetes mellitus (DM) ist ein klinisches Syndrom, dessen Häufigkeit in den westlichen Industriestaaten auf 1,5–2,5% geschätzt wird [1] und dessen Prävalenz genetisch bedingt in manchen Populationen (Pima-Indianer) allein für den Typ 2 bis zu 35% betragen kann [2]. Im allgemeinen wird jedoch der relative Anteil der nichtinsulinabhängigen (Typ 2) Diabetiker an der Gesamtprävalenz der Zuckerkrankheit mit 80–85% angegeben, so daß nur ein kleiner Anteil dem primär insulinabhängigen Diabetes des Typ 1 zuzuordnen ist.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Schliack V (1971) Die Verbreitung des Diabetes mellitus: Häufigkeit und Vorkommen in Europa und Amerika. In: Pfeiffer EF (Hrsg) Handbuch des Diabetes mellitus, Bd 2. Lehmanns, München, S 333–364
Bennett PH, LeCompte PM, Miller M, Rushforth NB (1976) Epidemiological studies of diabetes in the Pima Indians. Recent Prog Horm Res 32: 333–376
Waldhäusl W (1983) Therapeutische Möglichkeiten zur Normalisierung der Glukosehomöostase bei Diabetikern. Hämostaseologie 3: 140–148
Miller Leone V, Goldstein J (1972) More efficient care of diabetic patients in a country-hospital setting. N Engl J Med 286: 1388–1391
Green A, Solander F (1984) Epidemiological studies of diabetes mellitus in Denmark. 6. Use of hospital services by insulin treated patients. Diabetologia 26: 195–198
Deckert T, Poulsen JE, Larsen M (1979) The prognosis of insulin dependent diabetes mellitus and the importance of supervision. Acta Med Scand (Suppl) 624: 48–53
Panzram G, Zabel-Langhennig R (1981) Prognosis of diabetes mellitus in a geographically defined population. Diabetologia 20: 587–591
Bagdade JD et al. (1967) The significance of basal insulin levels in evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 46: 1549–1557
Beischer W et al. (1984) The therapeutic and prognostic relevance of the fast beta-cell stimulation capacity. In: Melchionda N, Horwitz DC, Schade DS (eds) Recent advances in obesity and diabetes research. Raven Press, New York, p 1
Beischer W et al. (1976) C-Peptid als Parameter für die orale Diabetestherapie. Verh Dtsch Ges Inn Med 82: 791–794
Beischer W et al. (1978) Humanes C-Peptid, Teil III: Sekretionsdynamik der Beta-Zellen erwachsener Diabetiker nach Glibenclamid-Glukose i.v. Klin Wochenschr 56: 111–120
Bodansky HJ et al. (1981) Plasma C-peptide in long-standing type 1 diabetics with and without microvascular disease. Diabete Metab 7: 265–269
Fajans SS et al. (1978) Clinical and etiologic heterogeneity of idiopathic diabetes mellitus. Diabetes 27: 1112–1125
Holman RR, Turner RC (1979) Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes. Diabetes 28: 227–230
Madsbad S (1983) Prevalence of residual B-cell function and its metabolic consequences in type 1 (insulin-dependent) diabetes. Diabetologia 24: 141–147
Madsbad S et al. (1981) Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 210: 153–156
Pfeifer MA et al. (1981) Insulin secretion in diabetes mellitus. Am J Med 70: 579–588
Pfeiffer EF et al. (1961) Über die Bestimmung von Insulin im Blute am epididymalen Fettanhang der Ratte mit Hilfe markierter Glukose. IV. Die Dynamik der Insulinsekretion des Stoffwechselgesunden und des Altersdiabetikers nach wiederholter Belastung mit Glukose, Sulfonylharnstoffen und menschlichem Wachstumshormon, ein Beitrag zur Pathogenese des menschlichen Altersdiabetes. Klin Wochenschr 39: 415–426
Pfeiffer EF, Raptis S (1972) Controlled extension of oral antidiabetic therapy on former insulin-dependent diabetics by means of the combined i.v. glibenclamide-glucose test. Diabetologia 8: 41–47
Pfeiffer EF et al. (1974) Einmalige intravenöse Glibenclamid-Glukose Belastung als Vorhersagetest. Dtsch Med Wochenschr 99: 1281–1294
Smith RBW et al. (1979) C-peptide response to glucagon in diabetics with and without complications. NZ Med J 89: 304–306
Tchobroutsky G (1978) Relation of diabetic control to development of microvascular complications. Diabetologia 15: 143–152
Adeniyi RO, Jones RH, Barnes DG, Gerlis LS, Sönksen PH (1983) Porcine and human insulin (Novo): a comparison of their metabolism and hypoglycaemic activity in normal man. Diabetes Care (Suppl 1 ) 6: 9–12
Arias P, Navascues I, Schäfauer G, Kerner W, Pfeiffer E (1983) Vergleichende Untersuchungen zur Wirksamkeit von semisynthetischem Humaninsulin und hochgereinigtem Schweineinsulin. Wien Med Wochenschr (Suppl) 76: 3
Bottermann P, Gyaram H, Wahl K, Ermler R, Lebender A (1981) Pharmacokinetics of biosynthetic human insulin and characteristics of its effect. Diabetes Care 4: 168–169
Dietze G, Wicklmayr M, Hepp KD, Bogner W, Mehnert H, Czempiel H, Henftling HG (1976) On gluconeogenesis of human liver. Accelerated hepatic glucose formation induced by increased precursor supply. Diabetologia 12: 555–561
Gutmann J, Rachel V, Brundl G (1969) Vergleichende Untersuchungen mit neuen rheographischen und plethysmographischen Durchblutungsmageräten. Elektromedizin 87: 38
Johansen K (1983) Human insulin — Medical progress? Metabolism 32: 528–532
Owens DR, Jones MK, Hayes TM, Heding LG, Alberti KGMM, Home PD, Burrin JM, Newcombe RG (1981) Human insulin: Study of safety and efficacy in man. Br J Med 282: 1264–1266
Sonnenberg GE, Berger M (1983) Human insulin: Much ado about one amino acid— Diabetologia 25: 457–459
Wicklmayr M, Dietze G (1979) Untersuchungen zur Insulinsensitivität von Leber und Muskulatur des Menschen. Verh Dtsch Ges Inn Med 85: 993–997
Christiansen AH (1973) Radioimmunoelectrophoresis in the determination of insulin binding to IgG. Methodological studies. Horm Metab Res 5: 147–154
Federlin K, Velcovsky HG (1974) IgE-Antikörper bei Patienten mit Insulinallergie. Verh Dtsch Ges Inn Med 80: 1613–1617
Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S (1983) Immunogenicity of recombinant DNA human insulin. Diabetologia 25: 465–469
Gambhir K, Archer J, Carter L (1977) Insulin radioreceptor assay or human erythrocytes. Clin Chem 23: 1590–1595
Laube H, Svedberg J, Velcovsky HG, Federlin K (1981) Biosynthetisches Humaninsulin — seine Wirkung auf Blutzucker, C-Peptid und Plasmacortisol beim Menschen. Verh Dtsch Ges Inn Med 87: 148–150
Schluter KJ (1983) Humaninsulin. Diabetes-Praxis 7: 1–7
Velcovsky HG, Federlin K (1982) Insulin specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin. Diabetes Care 5: 126–132
Andersen O (1975) The immunogenic properties of highly purified insulin preparations. The clinical importance of insulin-binding antibodies. Acta Endocrinol (Kbh) 78: 723–735
Asplin CM et al. (1978) Change of insulin dosage, circulating free bound insulin and insulin antibodies on transferring diabetics from conventional to highly purified insulin. Diabetologia 14: 99–105
Christiansen AH (1973) Radioimmunoelectrophoresis in the determination of insulin binding to IgG. Methological studies. Horm Metab Res 5: 147–154
Deckert T, Lorup B (1976) Regulation of brittle diabetes by a pre-planned insulin infusion programme. Diabetologia 12: 537–579
Deckert T, Lauritzen T (1982) Assessment of one-year insulin pump therapy. Diabetologia 23: 162–163
Federlin K et al. (1983) Immunologische Beobachtungen bei Primär-and Sekundärbehandlung von Diabetikern mit Humaninsulin. Miinch Med Wochenschr 125: 101–107
Irsigler K, Kritz H (1979) Long-term continous intravenous insulin therapy with a portable insulin dosage regulating apparatus. Diabetes 28: 196–203
Kurtz AB et al. (1978) Insulin-binding antibody: Reaction differences with bovine and porcine insulins. Diabetologia 15: 19–22
Koivisto VA et al. (1983) No evidence of amyloidosis in type I diabetics treated with continuous subcutaneous insulin infusion. Diabetes 32: 88–90
Levandoski LA et al. (1982) Localized skin reactions to insulin: insulin lipodystrophies and skin reactions to pumped subcutaneous insulin therapy. Diab Care 5: 6–10
Lougheed WD et al. (1980) Insulin aggregation in artificial delivery systems. Diabetologia 19: 1–9
Mauer SM et al. (1983) Failure to finf amyloidosis in dogs treated with long-term intravenous insulin delivered by a totally implantable pump. Diabetologia 25: 448–450
Neuzner J et al. (1981) Short term treatment with a portable insulin pump influences diabetic autonomic neuropathy. Diabetologia 21: 308
Neuzner J et al. (1983) Long-term intravenous insulin infusion therapy in patient with insulin dependent diabetes mellitus and Addison’s disease. In: Irsigler K, Kritz H, Lovett R (eds) Diabetes treatment with implantable insulin infusion systems. Urban and Schwarzenberg, Munich Vienna Baltimore, pp 103–109
Pickup JC et al. (1978) Continous subcutaneous insulin infusion: an approach to achieving normoglycaemia. Br Med J 1: 204–207
Pietri A et al. (1980) Changes in nerve conduction velocity after six weeks of glucoregulation with portable insulin infusion pumps. Diabetes 29: 668–671
Sachse G et al. (1983) Treatment with a portable insulin infusion system influences autonomic diabetic neuropathy of the cardiovascular system. In: Irsigler K, Kritz H, Lovett R (eds) Diabetes treatment with implantable insulin infusion systems. Urban and Schwarzenberg, Munich Vienna Baltimore, pp 201–203
Schiffrin A, Belmonte M (1982) Comparison between continuous subcutaneous insulin infusion and multiple injections of insulin. Diabetes 31: 255–264
Schulz G et al. (1983) Implantable insulin infusion devices in the therapy of type I diabetes. In: Irsigler K, Kritz H, Lovett R (eds) Diabetes treatment with implantable insulin infusion systems. Urban and Schwarzenberg, Munich Vienna Baltimore, pp 110–118
Slama G et al. (1974) One to five days of continuous intravenous insulin infusion on seven diabetic patients. Diabetes 23: 732–739
Teutsch SM et al. (1984) Mortality among diabetic patients using continuous subcutaneous insulin-infusion pumps. N Engl J Med 310: 361–368
Velcovsky HG, Federlin K (1982) Insulin-specific IgG and IgE antibody response in type I diabetic subjects exclusively treated with human insulin. Diab Care 5: 126–128
Viberti G et al. (1981) Correction of exercise induced microalbuminuria in insulin dependent diabetics after 3 weeks of subcutaneous insulin infusion. Diabetes 30: 818–823
Williamson JR et al. (1982) Secondary amyloidosis in (beagle) dogs receiving intravenous insulin via mechanical pumps. Diabetes 31: 50A
Yue DK et al. (1975) Antigenicity of “Monocomponent” pork insulin in diabetic subjects. Diabetes 24: 625–632
Boulton AJM, Drury J, Clarke B, Ward JD (1982) Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diab Care 5: 386–390
Irsigler K, Kunz KM, Owens DR, Regal H (eds) New approaches to insulin therapy. Lancaster, MTP Press Ltd., pp 437–441
Pietri A, Ehle AL, Raskin P (1980) Changes in nerve conduction velocity after six weeks of glucoregulation with portable insulin infusion pumps. Diabetes 29: 668–671
Tolaymat A, Roque JL, Rosso LS Jr (1982) Improvement of diabetic peripheral neuropathy with the portable insulin infusion pump. South Med J 75: 185–189
White NH, Skor D, Santiago JV (1982) Long-term effect of intensive insulin therapy (ITT) on peripheral (PN) and autonomic (AN) neuropathy in insulindependent diabetics (IDDs) (Abstract). Diabetes (Suppl) 31: 66A
Kästner E, Beyer J, Hassinger W, Schulz G, Cordes U (1980) Untersuchungen zum basalen und nahrungsabhängigen Insulinbedarf bei Diabetikern während kontinuierlicher intravenöser Insulininfusion mit tragbaren Minipumpen im Kurz-und Langzeitversuch. Aktuel Endokrinol Stoffwechselkr 1: 185
Blackshear PJ, Rohde TD, Prosl F, Buchwald H (1979) The implantable pump: a new concept of drug delivery. Med Prog Technol 6: 149
Buchwald H, Rohde TD, Dorman FD, Skagoon JG, Wigness BD, Blackshear PJ, Varco RL (1980) A totally implantable drug infusion device: Laboratory and clinical experience using a model with single flow rate and new design for modulation insulin infusion. Diab Care 3: 351–358
Schulz G, Beyer J, Hogan M, Cordes U, Kempf P (1983) Implantable insulin infusion devices in the therapy of type I diabetics. In: Irsigler K, Kritz H, Lovett R (eds) Diabetes treatment with implantable insulin infusion system. Urban und Schwarzenberg, München Wien Baltimore, p 110
Service FJ, Molnar GD, Rosewear JW, Ackermann E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions: a measure of diabetic instability. Diabetes 19: 644–655
Schlichtkrull JO, Munk O, Jersild M (1965) The M-value an index of blood-sugar control in diabetics. Acta Med Scand 177: 95–102
Geisen K, Gerlach MH, Keil M (1981) Morphological in pancreatectomized dogs within an implanted insulin dosing device: Tissue reactions to the pump housing and to the vascular catheter. Horm Metab Res 15: 4–10
Kashiwagi S, Morguet A, Schmitt V, Schonwald F, Kiesel U, Herberg L, Müntefering H (1981) Komplikationen der kontinuierlichen Insulininfusion bei Ratten. Acta Endokrinol (Kbh) 2: 95
Irsigler K, Kritz H (1982) Improvement of metabolic control with implanted insulin delivery devices in five diabetic patients-Long term feasibility. Diabetes 31: 654
Kritz H, Hagemüller G, Lovett R, Irsigler K (1983) Implanted constant basal rate insulin infusion devices for type 1 (insulin-dependent) diabetic patients. Diabetologia 25: 78–81
Pozza G, Spotti D, Micossi P, Christallo M, Melandri M, Piatri PM, Monti LD, Pontiroli AE (1983) Long-term continuous intraperitoneal insulin treatment in brittle diabetes. Br Med J 286: 255–256
Krzentowski G, Pirnay F, Pallikarakis N, Luyckx AS, Lacroix M, Mosora F, Lefebvre PJ (1981) Glucose utilization during exercise in normal and diabetic subjects. Diabetes 30: 983–989
Berger M, Berclefeld P, Clippers HJ, Drost H, Kley HK, Muller WA, Wiegelmann W, Zimmermann-Teltschow, Gries A, Krüskemper HL, Zimmermann H (1977) Metabolic and hormonal effects of muscular exercise in juvenile type diabetics. Diabetologia 13: 355–365
Koivisto VA, Felig P (1977) Effects of exercise on insulin release from injection sites in diabetic man. Diabetes 26: 357–361
Martin MJ, Robbins DC, Bergenstal R, La Grange B, Rubenstein AH (1982) Absence of exercise induced hypoglycemia in type I diabetic patients during maintenance of normoglycemia by short term open loop insulin infusion. Diabetologia 23: 337–342
Costill DL, Benett A, Branam G, Eddy D (1973) Glucose ingestion at rest and during prolonged exercise. J Appl Physiol 34: 764–769
Caron D, Poussier P, Marliss EB, Zinman B (1982) The effect of postprandial exercise on meal related glucose intolerance in insulin dependent diabetic individuals. Diab Care 5: 364–369
WHO Expert Committee on Diabetes Mellitus (1980) Second report. WHO Technical Report Series 646, Geneva
Fajans SS, Conn JW (1959) The early recognition of diabetes mellitus. Ann NY Acad Sci 82: 208–218
WHO Expert Committee on Diabetes Mellitus (1956) First report. WHO Technical Report Series 310, Geneva
Jarrett RJ, Keen H, Fuller JH, McCartney M (1979) Worsening to diabetes in men with impaired glucose tolerance („borderline diabetes“). Diabetologia 16: 25–30
Keen H, Jarrett RJ, McCartney P (1982) The ten-year follow-up of the Bedford survey (1962–1972): Glucose tolerance and diabetes. Diabetologia 22: 73–78
Köbberling J, Appels A, Köbberling G, Creutzfeldt W (1969) Glucosebelastungstests bei 727 Verwandten 1. Grades von Altersdiabetikern. Dtsch Med Wochenschr 94: 416–421
Köbberling J, Kattermann R, Arhold A (1975) Follow up of „non diabetic“ relatives of diabetics by retesting oral glucose tolerance after 5 years. Diabetologia 11: 451–456
Köbberling J (1980) Zur Wertigkeit des oralen Glucosetoleranztests. Internist 21: 213–219
Köbberling J (1982) Der prädiktive Wert diagnostischer Maßnahmen. Dtsch Med Wochenschr 107: 591–595
Haslbeck M (1981) Diagnostische Probleme bei Diabetes mellitus. Internist 22: 187–196
Brekke IB, Aluments J, Sundler F (1983) The duct-ligated pancreas transplant and its effect on the islet cellular composition of the host pancreas. Cell Tissue Res 231: 205–213
Bretzel RG, Federlin K (1980) Islet transplantation in experimental diabetes mellitus of the rat. Biochemical and morphological findings. In: Bibergeil H, Zühlke H, Poser U (eds) Early diabetes. Pathogenesis, diagnosis, prevention. Central Institute for Diabetes „Gerhardt Katsch`, Karlsburg, p 290
Bretzel RG, Manns E, Schomber C, Federlin K (1978) Die Leber als Implantationsort far Langerhanssche Inseln beim experimentellen Diabetes mellitus. Verh Dtsch Ges Inn Med 84: 1213–1217
Kramp RC, Burr IM (1981) Subcutaneous, isogeneic transplantation of duct-ligated pancreas in streptozotocin-diabetic mice. Relationships between carbohydrate tolerance and hormone content in transplant or host pancreas. Diabetes 30: 857–864
Trimble ER, Karakash C, Malaisse-Lagae F, Vassutine I, Orci L, Renold AE (1980) Effects of intraportale islet transplantation on the transplanted tissue and the recipient pancreas. I. Functional studies. Diabetes 26: 341–347
Rüdiger, HW, Dreyer M, Kühnau J, Bartelheimer H (1983) Familial insulin-resistant diabetes secondary to an affinity defect of the insulin receptor. Hum Genet 64: 407–411
Pilch PF, Czech MP (1979) Interaction of cross-linking agents with the insulin effector system of isolated fat cells. J Biol Chem 254: 3375–3381
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1984 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Waldhäusl, W. et al. (1984). Postersession III. In: 90. Kongreß. Verhandlungen der Deutschen Gesellschaft für Innere Medizin, vol 90. J.F. Bergmann-Verlag, Munich. https://doi.org/10.1007/978-3-642-85457-6_67
Download citation
DOI: https://doi.org/10.1007/978-3-642-85457-6_67
Publisher Name: J.F. Bergmann-Verlag, Munich
Print ISBN: 978-3-8070-0342-9
Online ISBN: 978-3-642-85457-6
eBook Packages: Springer Book Archive